Table of Contents
Journal of Allergy
Volume 2010 (2010), Article ID 691425, 7 pages
Research Article

FeNO as a Marker of Airways Inflammation: The Possible Implications in Childhood Asthma Management

1Allergological and Pneumological Service, Department of Pediatric, University “G. D'Annunzio”, 66100 Chieti, Italy
2Department of Pediatric, University “G. D'Annunzio”, 66100 Chieti, Italy

Received 16 September 2009; Revised 30 January 2010; Accepted 1 March 2010

Academic Editor: Massimo Triggiani

Copyright © 2010 Marcello Verini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The aim of this study was to verify FeNO usefulness, as a marker of bronchial inflammation, in the assessment of therapeutic management of childhood asthma. We performed a prospective 1-year randomized clinical trial evaluating two groups of 32 children with allergic asthma: “GINA group”, in which therapy was assessed only by GINA guidelines and “FeNO group”, who followed a therapeutic program assessed also on FeNO measurements. Asthma Severity score (ASs), Asthma Exacerbation Frequency (AEf), and Asthma Therapy score (ATs) were evaluated at the start of the study (T1), 6 months (T2), and 1 year after (T3). ASs and AEf significantly decreased only in the FeNO group at times T2 and T3 (p[T1-T2] = 0.0001, and p[T1-T3] = 0.01; p[T1-T2] = 0.0001; and p[T1-T3] < 0.0001, resp.). After six months of follow-up, we found a significant increase of patients under inhaled corticosteroid and/or antileukotrienes in the GINA group compared to the FeNO group ( 𝑃 = . 0 2 ). Our data show that FeNO measurements, might be a very useful additional parameter for management of asthma, which is able to avoid unnecessary inhaled corticosteroid and antileukotrienes therapies, however, mantaining a treatment sufficient to obtain a meaningful improvement of asthma.